Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill, Wendy A. Kellner, Alexandra Stowell, Christian Sherk, Kristen Wong, Sarath Pathuri, Jacques Briand, Michael Steidel, Philip Chapman, Arthur Groy, Ashley K. Wiseman, Charles F. McHugh, Nino Campobasso, Alan P. Graves, Emma Fairweather, Thilo Werner, Ali Raoof, Roger J. ButlinLourdes Rueda, John R. Horton, David T. Fosbenner, Cunyu Zhang, Jessica L. Handler, Morris Muliaditan, Makda Mebrahtu, Jon Paul Jaworski, Dean E. McNulty, Charlotte Burt, H. Christian Eberl, Amy N. Taylor, Thau Ho, Susan Merrihew, Shawn W. Foley, Anna Rutkowska, Mei Li, Stuart P. Romeril, Kristin Goldberg, Xing Zhang, Christopher S. Kershaw, Marcus Bantscheff, Anthony J. Jurewicz, Elisabeth Minthorn, Paola Grandi, Mehul Patel, Andrew B. Benowitz, Helai P. Mohammad, Aidan G. Gilmartin, Rab K. Prinjha, Donald Ogilvie, Christopher Carpenter, Dirk Heerding, Stephen B. Baylin, Peter A. Jones, Xiaodong Cheng, Bryan W. King, Juan I. Luengo, Allan M. Jordan, Ian Waddell, Ryan G. Kruger, Michael T. McCabe

Research output: Contribution to journal › Article › peer-review

92 Scopus citations

Fingerprint

Dive into the research topics of 'Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences